当前位置: X-MOL 学术Nat. Rev. Endocrinol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Therapeutic breakthroughs for metastatic thyroid cancer.
Nature Reviews Endocrinology ( IF 31.0 ) Pub Date : 2020-02-01 , DOI: 10.1038/s41574-019-0307-2
Vera Tiedje 1 , James A Fagin 1
Affiliation  

Multikinase inhibitors are effective treatments for thyroid cancers, acting primarily as antiangiogenic agents. This year, advances have been made in selective targeting of RET and BRAF in patients with medullary and anaplastic thyroid cancers, respectively. However, Hürthle cell carcinomas have a unique genomic landscape with no dominant truncal drivers, precluding simplistic approaches to therapeutic targeting.

中文翻译:

转移性甲状腺癌的治疗突破。

多激酶抑制剂是甲状腺癌的有效治疗方法,主要用作抗血管生成剂。今年,RET 和 BRAF 的选择性靶向治疗分别在甲状腺髓样癌和间变性甲状腺癌患者中取得了进展。然而,Hürthle 细胞癌具有独特的基因组景观,没有主要的躯干驱动因素,排除了治疗靶向的简单方法。
更新日期:2019-12-09
down
wechat
bug